Division of Vascular Medicine, Department of General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands.
J Intern Med. 2010 Dec;268(6):567-77. doi: 10.1111/j.1365-2796.2010.02277.x.
To compare apolipoprotein B (apoB), non-high-density lipoprotein-cholesterol (non-HDL-c) and low-density lipoprotein-cholesterol (LDL-c) for identifying individuals with a deteriorated cardiovascular (CV) risk profile, including a panel of subclinical atherosclerosis measurements and prevalent cardiovascular disease (CVD) in a Dutch population-based cohort.
Clinical and biochemical measurements and a panel of noninvasive parameters of subclinical atherosclerosis were determined in 1517 individuals, aged 50-70 years.
Both men and women with increasing levels of apoB and non-HDL-c were more obese, had higher blood pressure and fasting glucose levels, and a more atherogenic lipid profile. Furthermore, compared to the reference group (composed of those with apoB, non-HDL-c and LDL-c levels in the bottom quartiles), participants with high apoB and high non-HDL-c levels had a lower ankle-brachial index at rest (-3.5% and -3.1%, respectively) and after exercise (-6.3% and -4.7%, respectively), a thicker near wall (+4.8% and +4.2%, respectively), far wall (both +6.2%), and mean intima-media thickness (+5.7% and +5.3%, respectively) and more plaques (+54.2% and +54.3%, respectively). In addition, they also showed increased stiffness parameters (e.g. pulse wave velocity both +3.6%). Less clear differences in CV risk profile and subclinical atherosclerosis parameters were observed when participants were stratified by LDL-c level. Furthermore, apoB but not LDL-c detected prevalent CVD, and non-HDL-c only detected prevalent CVD in men. The discriminatory power for prevalent CVD expressed as area under the receiver operating characteristic curve was 0.60 (P < 0.001) for apoB, 0.57 (P = 0.001) for non-HDL-c and 0.54 (P = 0.108) for LDL-c.
Our data support the use of first apoB and secondly non-HDL-c above LDL-c for identifying individuals from the general population with a compromised CV phenotype.
为了比较载脂蛋白 B(apoB)、非高密度脂蛋白胆固醇(non-HDL-c)和低密度脂蛋白胆固醇(LDL-c)在识别心血管(CV)风险谱恶化的个体方面的作用,包括荷兰人群队列中的亚临床动脉粥样硬化测量和现患心血管疾病(CVD)的指标。
在 1517 名年龄在 50-70 岁的个体中,测定了临床和生化测量值以及亚临床动脉粥样硬化的一系列非侵入性参数。
apoB 和 non-HDL-c 水平升高的男性和女性均更肥胖,血压和空腹血糖水平更高,血脂谱更具致动脉粥样硬化性。此外,与参考组(由 apoB、non-HDL-c 和 LDL-c 水平处于最低四分位数的个体组成)相比,apoB 高和 non-HDL-c 水平高的患者静息时踝臂指数较低(分别为-3.5%和-3.1%),运动后更低(分别为-6.3%和-4.7%),近壁更厚(均为+4.8%和+4.2%),远壁(均为+6.2%),平均内膜中层厚度(均为+5.7%和+5.3%)和斑块更多(分别为+54.2%和+54.3%)。此外,它们还表现出僵硬参数的增加(例如,脉搏波速度均为+3.6%)。当按 LDL-c 水平对参与者进行分层时,CV 风险谱和亚临床动脉粥样硬化参数的差异不太明显。此外,apoB 而非 LDL-c 可检测到现患 CVD,non-HDL-c 仅可检测到男性现患 CVD。以接受者操作特征曲线下面积表示的现患 CVD 的判别能力,apoB 为 0.60(P<0.001),non-HDL-c 为 0.57(P=0.001),LDL-c 为 0.54(P=0.108)。
我们的数据支持使用 apoB 而非 LDL-c 来识别一般人群中具有受损 CV 表型的个体。